We have used the multifunctional transforming protein, simian virus 40 T antigen, as a probe to study the mechanisms of cell growth regulation in the intact organism. T antigen appears to perturb cell growth, at least in part, by stably interacting with specific cellular proteins that function to maintain normal cell growth properties. Experiments in cultured cells indicate that at least three distinct regions of simian virus 40 T antigen have roles in transformation. Two regions correlate with the binding of known cellular proteins, p53, pRB, and p107. A third activity, located near the amino terminus, has been defined genetically but not biochemically. By targeting expression of wild-type and mutant forms of T antigen to distinct cell types in transgenic mice, we have begun to systematically determine which activities play a role in tumorigenesis of each cell type. In this study, we sought to determine the role of the amino-terminal transformation function with such an analysis of the T-antigen mutant d11135. This protein, which lacks amino acids 17 to 27, retains the p53-, pRB-, and p107-binding activities yet fails to transform cells in culture. To direct expression in transgenic mice, we used the lymphotropic papovavirus transcriptional signals that are specific for B and T lymphocytes and the choroid plexus epithelium of the brain. We show here that although defective in cell culture, d11135 specifically induced the development of thymic lymphomas in the mouse. Expression of the protein was routinely observed in B-and T-lymphoid cells, although B-cell abnormalities were not observed. Choroid plexus tumors were observed only infrequently; however, d11135 was not consistently expressed in this tissue. Within a given transgenic line, the penetrance of T-cell tumorigenesis was 100%X but appeared to require secondary events, as judged from the clonal nature of the tumors. These experiments suggest that the amino-terminal region of T antigen has a role in the transformation of certain cell types (such as fibroblasts in culture and B lymphocytes) but is dispensable for the transformation of T lymphocytes.
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Simian virus 40 (SV40) large T antigen efficiently disrupts normal cell growth control in a variety of cell types in culture and in test animals (reviewed in references 17 and 29) . The diversity of cells susceptible to the effects of T antigen has been demonstrated most dramatically in transgenic mice, in which the growth properties of over 20 cell types have been altered by this protein (reviewed in references 1 and 22) . Current hypotheses suggest that T antigen induces neoplastic transformation by direct interaction with cellular proteins that normally function to regulate cell proliferation (18, 20, 27) . Genetic analyses of T antigen in cultured cells indicate that the protein possesses at least three transforming functions (10, 35, 42, 52) . One of these functions corresponds to the ability of T antigen to bind both pRB (9) and p107 (12, 15) and requires amino acids 105 to 114. A second activity correlates with the p53-binding function of T antigen (amino acids 271 to 517) (38, 39, 46, 52) . Since both pRB and p53 can inhibit the proliferation of cells in culture and are often lost or altered in certain human tumors (reviewed in references 28 and 34), T antigen may induce transformation simply by interfering with their normal functions. The function of p107
is not yet known, although it shares several properties with pRB, including binding to the same region of T antigen (12, 15) , interaction with some of the same cellular proteins (reviewed in reference 37), and homology with a region referred to as the pocket (16) .
A third transforming function of T antigen, which appears to reside near the amino terminus, is distinct from pRB/p1O7 and p53 binding, but its cellular target (s) is not yet known. Evidence for the existence of this activity includes the following observations: first, elimination of pRB/plO7 and p53-binding reduces but does not abolish transformation of certain cell lines (31, 42, 45) ; second, mutants with deletions in the first exon (amino acids 1 to 81) that retain the ability to bind pRB/p1O7 and p53 are defective for transformation in culture (6, 15, 35, 36, 39, 52) ; and third, a stable fusion protein containing the pRB-binding region of polyomavirus large T antigen and the p53-binding domain located within the carboxyl region of SV40 T antigen does not transform cells in culture (32) .
The role in transformation of each T-antigen activity, either alone or in concert with one another, is not completely understood. In cultured cell assays, some cell types (such as REF52) seem to require all three activities for transformation, while others (such as C3H1OT1/2) do not (35, 41, 42, 47, 52) . Thus, the type of cell and/or its state of differentiation may be important parameters in determining the response to oncogene action. Since T antigen encodes multiple transformation-related activities, the subset of T-antigen functions needed and the corresponding target proteins could differ among cell types. Alternatively, since transformation assays have largely been carried out in cultured cells, the observed differences in requirements for transformation may reflect different growth conditions and/or the accumulation of ab-normal genetic changes. We have developed transgenic mouse models that explore the role of T-antigen transforming activities in defined cell types. By introducing T-antigen mutants into transgenic mice under the control of a cellspecific promoter, we have begun to test the hypothesis that different subfunctions of T antigen are required for transformation depending on the cell type or developmental stage.
Previously, we analyzed wild-type and mutant SV40 T antigens for their ability to induce tumors in three cell types with distinct normal growth properties. One cell type, the choroid plexus epithelium of the brain, normally differentiates during fetal life and stops dividing within 2 weeks after birth (33) . The other cell populations, the B-and T-lymphoid cells, undergo proliferation and differentiation throughout the life of the animal (24) . We targeted transgene expression to all three cell types by using the lymphotropic papovavirus (LPV) transcriptional signals (3) . Under LPV control, wildtype SV40 T antigen induces choroid plexus tumors in the majority of founder mice within 3 to 4 weeks of life and does not require secondary genetic changes (5) . A direct correlation exists between T-antigen expression, morphological transformation, and proliferation of the choroid plexus epithelial cells, resulting in uniform expansion of the entire tissue (5) . Lymphoproliferative disorders of both B and T cells are also evident in these mice (3, 4) .
Our previous examination of T-antigen mutants defective in pRB/p107 and/or p53 binding in this transgenic model system indicates that the relevant targets of T antigen could differ depending on the cell type (4) . While loss of the C-terminal four-fifths of the protein (including the p53-binding region) eliminates the appearance of lymphoma, the remaining N-terminal fragment of 121 amino acids still induces the formation of choroid plexus tumors. A mutant with a single amino acid change that simultaneously disrupts pRB/p107 and p53 binding is unable to induce both lymphoma and choroid plexus tumors (4) . Interestingly, this protein induces hyperplasia in the choroid plexus, an observation which supports the notion that a T-antigen activity other than pRB/p107 and p53 binding can alter cell growth control.
In this report, we explore the role of the amino-terminal activity in this transgenic model system by using a deletion mutant of SV40 T antigen that is defective for transformation in cultured cells. This mutant protein, d11135, contains a deletion of amino acids 17 to 27 yet retains the ability to bind pRB, p107, and p53 (15, 35, 39) . This approach uncovered the first known susceptible target cell for this mutant protein, in that d11135 specifically induced the development of T-cell lymphomas.
MATERUILS AND METHODS Construction of pLST1135. Plasmid LST1135 was constructed from two intermediate plasmids, p1135T/t and pLST1135T/t. To create p1135T/t, a plasmid containing the complete SV40 mutant viral genome in pBR322, pd11135 (39) , was digested with StuI and BamHI. The 2.4-kb T-antigen coding fragment was isolated and inserted into the SmaI site of pGEM3. An Asp 718-to-EcoRI fragment, containing the LPV control region (3), was inserted into the same sites of p1135T/t. pLST1135T was generated by substituting the 1,590-bp EcoNI fragment of pLST1135T/t for the corresponding fragment of pSVT (5) . Since T-cell depletion of spleen cells. Spleen cell suspensions were prepared as described above for flow cytometry. The cells were incubated at 107 cells per ml with anti-Thyl.2 for 30 min at 4°C, washed once, and resuspended at 107/ml in rabbit complement (Cedar Lane) for 40 min at 37°C. The cells were washed extensively, recounted, and pelleted for use in immunoprecipitation reactions as described above. The composition of cells after T-cell depletion was verified by flow cytometry as described above.
Immunofluorescence. Thymocyte suspensions were prepared as described above for flow cytometry. Cell suspensions or 6-,um tissue sections were placed on polylysinecoated slides (0.5 x 106 cells per slide), air dried, and stored at -80°C. Slides were fixed with 2% paraformaldehyde in 50 The fragment consists of the 580-bp LPV control region ( ) and the mutant SV40 T-antigen coding region (El) containing two deletions, the d11135 amino-terminal deletion and a deletion within the intron which abolishes the production of small t antigen. Shaded boxes represent exons. Linear diagrams of wild-type (WT) and d11135 T antigens are shown in panel B. Regions involved in binding pRB, p107, and p53 are indicated. The putative amino-terminal transforming activity is labeled "X" to reflect the fact that biochemical functions which correlate with this activity have not been fully characterized; p300 binding represents one candidate. different LST1135-11 mice were averaged. Cell suspensions from each mouse contained similar numbers of T-antigenpositive cells.
RESULTS
dl1135 T-antigen activity in transgenic mice. To determine the role of the amino-terminal transforming activity of T antigen in tumorigenesis, transgenic mice that harbored the LST1135 transgene were generated. This fusion gene encodes the mutant SV40 large T-antigen protein, d11135, under the control of the LPV enhancer and early promoter ( Fig. 1) . In transgenic mice, the LPV regulatory region directs expression to the B and T lymphocytes and to the choroid plexus epithelium (3). Previously, we described the analysis of similar hybrid genes encoding the wild-type protein and three other mutant forms of T antigen (3, 4) . As with our other studies, the LST1135 transgene harbors a deletion from nucleotides 4854 to 4586 of SV40 that disrupts the expression of small t antigen as a result of removal of the small t-specific splice donor site (8) . This mutation does not affect the expression of large T antigen since it lies entirely within the large T intron. The d11135 mutation deletes nucleotides 5116 to 5084, resulting in the in-frame loss of amino acids 17 to 27 (Fig. 1B [39] ). The d11135 protein is unable to transform the cultured cells which have so far been tested, including C3H1OT1/2 (42a), REF52 (35, 39) , primary baby rat kidney (49) , and CREF (35) cells. However, it retains the ability to bind pRB (15), p107 (15) , and p53 (36) .
The LST1135 fusion gene was introduced into the mouse germ line by pronuclear microinjection. Twenty-six founder mice were generated. Mice that developed life-threatening abnormalities and all remaining mice at 13 months of age were sacrificed for analysis.
In previous experiments, wild-type T antigen driven by the LPV control region (the LST transgene) predominantly -mimir x VOL. 13 induced rapid choroid plexus tumorigenesis (5) . Signs of lymphoproliferation also appeared in these mice, although early death precluded assessment of malignant lymphoma (see the introduction) (3, 5) . In contrast to wild-type T antigen, the predominant phenotype induced by d11135 was thymic lymphoma. The LST1135 founder mice that developed abnormal phenotypes are shown in Table 1 , and a graph of their survival is shown in Fig. 2 . Thirteen of the twenty-six founder mice (50%) were sacrificed upon showing signs of distressed breathing due to extensive thymic enlargement. The spleens of some of these mice were also enlarged. Histological examination of abnormal thymuses and spleens showed extensive population by morphologically similar lymphocytes (not shown). Only two of the LST1135 founder mice developed choroid plexus tumors (9% of these founder mice compared with 75% with wildtype T antigen) (5). These tumors also arose much later (222 and 250 days) than did those induced by wild-type T antigen (between 21 and 35 days of age). The remaining founder mice were sacrificed at 13 months of age and examined. Eight of these mice showed no gross abnormalities, one had an enlarged thymus characteristic of thymoma, and two had developed sarcomas (Table 1) .
For further analysis of the thymic phenotype, a line of mice was established from the LST1135-11 founder (Table  1 ). All transgenic mice in this lineage developed thymic lymphomas that became life threatening by about 5 months of age (Table 1 and Fig. 2 ). While the LST1135 founder mice died within a rather broad period of time (150 to 318 days), the mice of the LST1135-11 lineage developed disease within narrow time frame (132 to 212 days; Fig. 2 Table 1 for the LST1135 phenotypes). Open circles indicate LST1135 founder animals that developed choroid plexus tumors rather than T-cell lymphoma (filled circles). Mice which were sacrificed at the end of the study are considered survivors. Mice of the LST1135-11 F2 generation were born in several different litters at various times.
phenotype could have indicated that the need for additional genetic changes limited the penetrance of tumorigenesis. However, the transgene demonstrated 100% penetrance of the phenotype in the LST1135-11 lineage (Fig. 2) . The lower frequency of tumor development in the LST1135 founder mice most likely reflects the influence of some insertion sites on transgene expression. Indeed, founder mice that did not develop an abnormal phenotype did not detectably express the d11135 protein (see below).
Expression of d11135 in transgenic mice. A variety of tissues from all founder mice and several mice of the LST1135-11 lineage were examined for d11135 expression by immunoblotting analysis. In mice which developed phenotypes, the d11135 protein was commonly expressed in thymuses and spleens, consistent with the specificity of the LPV regulatory region (3, 5) . A representative immunoblotting analysis is shown in Fig. 3A well as T cells in LST1135-11 mice, T cells were depleted from spleen cell suspensions by treatment with anti-Thyl.2 and complement prior to immunoblotting. Flow cytometry confirmed enrichment of the population for B cells and removal of 90% or more of the T cells (Fig. 3B) . Three mice were analyzed, and data from two representative mice are shown in Fig. 3C . All three mice expressed significant levels of d11135 in the spleen cells after T-cell depletion (Fig. 3C , lanes 6 and 7, and data not shown). Two d11135-specific bands were apparent in the B-cell samples from two mice (lane 9 and data not shown). The faster-migrating form was often expressed in the spleens, but not in thymuses, of LST1135 mice. Since this form was not always present (for example, mouse 5123; Fig. 3C ), the significance of this observation, if any, is not clear. The d11135 in all B-cellenriched samples showed the characteristic reduction of reactivity with PAb419 (lanes 8 and 10).
Complex formation between p53 and d11135 in spleens and thymuses was demonstrated by immunoprecipitation of T antigen with PAb421, a monoclonal antibody that recognizes p53 (Fig. 3A, lanes 16 and 18) , and by coimmunoprecipitation of p53 with the T-antigen-specific antibody PAblOl (lanes 22 and 24) . The ability of d11135 to bind p53 was indistinguishable from that of wild-type T antigen (lanes 3 and 7). In two independent experiments, quantification of p53 and d11135, both free and in complex, indicated that all of the detectable p53 in the thymus was complexed to 43 and 56% of the d11135 T antigen (data not shown). In the spleen, 64 and 89% of the p53 was complexed to 43 and 52% of the total d11135 protein (data not shown). and nontransgenic littermates of LST1135-11 mice (between 1.0 and 8.0 months of age) were also examined as controls. Cell suspensions were prepared from spleens and thymuses and were doubly stained in a series of reactions involving FITC-and biotin-labeled antibodies recognizing the following pairs of cell surface markers: CD4 and CD8, CD3 and CD8 or CD4, and Thyl.2 and B220. The latter pair was used to distinguish T cells (Thyl.2+) and B cells (B220+). A normal distribution of maturing lymphocytes was observed in the nontransgenic control thymocyte populations (Table 2 and Fig. 4 , controls 1 and 2, and data not shown). A similar distribution was obtained with LST1135-11 transgenic mice which were around 1 month of age (Table 2 and Fig. 4 , mice 5003, 5004, and 5010).
In contrast, thymocytes from older LST1135-11 mice exhibited a progressive divergence from the normal pattern with increasing age (Table 2 and Fig. 4B and C analyzed for the presence of V,3, VP5 to -9, and V,B11. Four of these tumors were also examined for V12, -10, and -14. The heterogeneous T-cell populations from normal mice contain many different clones, each of which expresses a single variant of the TcR complex. In normal BDF1 mice VP3, -5, -6, -7, -9, and -11 together comprise about 5.5% of TcR-positive cells, while V12, -8, -10, and -14 comprise 7.9, 16.3, 10.4, and 8%, respectively (Table 3) . Additional TcR variants not assayed in these studies comprise the remaining 52% of the TcR-positive T cells in normal mice.
All transgenic thymuses examined contained an abnormal distribution of TcR subtypes ( T-cell population is often relatively homogeneous and suggest that a clonal transformation event has occurred in most mice.
Since thymomas generally consisted of a single class of T cells, we analyzed the expression of d11135 within the T-cell population to determine whether clonality of the tumors resulted from clonal expression of the transgene. Single cell thymocyte suspensions from 5 nonlymphomic LST1135-11 mice were examined by immunohistochemistry. Data from a representative mouse (5120) are shown in Fig. 5 . The normal distribution of T-cell subsets was confirmed by FACS analysis of each suspension ( Fig. SA and D) . In each case, the majority (average, 98%), not a subset, of thymocytes expressed the d11135 T antigen (compare Fig. E and F for a representative field). Immunofluorescence of tissue sections showed a similarly high percentage of cells expressing d11135 (not shown). Thus, predominance of a single cell type in lymphomas was not merely the result of restricted T-antigen expression and probably reflects the involvement of secondary events (see Discussion). DISCUSSION We have used the multifunctional transforming protein, SV40 T antigen, to probe mechanisms of cell growth control in the intact organism. By targeting expression of mutant forms of T antigen to specific cell types in transgenic mice, we can test whether the cellular targets of T antigen have ubiquitous or cell-type-specific roles in growth regulation. In this report, we demonstrate that a mutant form of T antigen, d11135, which is defective for transformation of certain cells in culture, induces thymic lymphoma in transgenic mice.
Mutant d11135 represents a class of mutants with deletions near the amino terminus that retain the ability to bind p53, pRB, and p107. Together with results of cultured cell exper-VOL. 13, 1993 iments, the study presented here suggests that the aminoterminal activity impaired in d11135 is necessary to induce the transformation of certain cell types but is dispensable for transformation of others.
Mechanism of dl1135-induced lymphomagenesis. SV40 T antigen induces both B-and T-cell lymphomas in transgenic SV40 T antigen caused the development of thymoma which followed an initial reduction in the CD4+ CD8+ population. T-cell lines established from the tumors were CD3+, with varied CD4 and CD8 profiles (19) .
Consistent development of T-cell lymphoma in the LST1135 mice described here permitted the systematic analysis of disease progression. In the LST1135-11 line, the abnormal distribution of T cells first appears in the thymus after about 2 months of age. By 4 to (19) .
In all mice in this study, the affected T-cell population appears to be a mature cell, characterized by a high level of surface CD3. Mature cells may be the only targets for transformation by T antigen. Alternatively, an immature cell could be affected at any particular stage of T-cell differentiation but may proceed along the normal pathway with disturbed growth properties. In either case, T antigen could contribute to tumorigenesis by extending the survival of the T cells such that the probability of additional genetic lesions is increased. One way to achieve increased survival is by interference with the normal apoptosis, or programmed cell death, pathway. Since the apoptosis gateway for T cells occurs just prior to the final maturation step, this hypothesis would be consistent with the observation that mature T cells comprise T-antigen-induced thymomas. Interestingly, p53 was recently shown to induce apoptosis in a myeloid leukemia cell line (51) and in a colon cell line in culture (40) . Moreover, thymocytes from p53 null mice fail to apoptose in response to irradiation (30 (50) .
The observation that the d11135 protein is expressed in B cells but fails to produce a phenotype there indicates that the ability of T antigen to complex pRB, p107, and p53 is not sufficient to perturb the growth of these cells. This observation further suggests that the amino-terminal transformation function(s) is required to elicit B-cell lymphoma even though it is dispensable for the production of T-cell tumors. Further studies will be required to determine which B-cell types express the protein and whether the level of protein per cell is comparable to that observed in T cells or in lymphomic B cells expressing wild-type T antigen. One unexplained observation from this study is that a faster-migrating form of d11135 is often observed only in spleen and is enriched in purified B cells. Whether this form results from proteolytic cleavage or from modifications specific to B cells requires further characterization.
Do the cellular targets of T antigen have cell-type-specific roles in growth control? This report represents our first look at a mutant defective in the amino-terminal transformation activity of T antigen in the intact organism and suggests the possibility of a cell-specific role in growth control. The results obtained here constitute the first demonstration that this mutant can transform cells at all. Whether the T-cell population is the only permissive cell type for d11135-induced transformation will require studies in which the expression of the protein is directed to many more cell types in transgenic mice. Since the amino acids deleted in d11135 lie within the region also present in small t antigen, we emphasize that the present study of d11135 and our previous studies of T antigen in transgenic mice (3, 4) were carried out in the absence of small t antigen, excluding the possibility that any effects measured in this study were due to changes in small t antigen.
The biochemical nature of the transforming activity disrupted by deletions near the amino terminus has not yet been fully characterized. Evidence suggests that in addition to binding the cellular proteins p53, pRB, and p107, T antigen may bind to p300, a protein identified by its interaction with the ElA protein of adenovirus (14, 48) . This binding property is associated with the ability of ElA to transform cells in culture; T antigen can complement a p300-binding-defective mutant of ElA for transformation (49) , suggesting that a VOL. 13, 1993 similar activity may be present. Recently a cDNA encoding p300 was isolated and a glutathione S-transferase/p300 fusion protein was shown to bind to SV40 T antigen in vitro. While this binding activity has not been fully characterized, preliminary evidence suggests that it maps near the amino terminus (13) . Thus, p300 binding is a candidate for a biochemical activity affected in d11135.
The results from this study combined with our previous analysis of T-antigen mutants suggest that different T-antigen transformation functions may have cell-specific effects. For example, a mutant which encodes only the aminoterminal fragment of 121 amino acids, d11137, is unable to induce lymphoid tumors in both B and T cells but still induces choroid plexus tumors (reference 4 and our unpublished results). This mutant protein contains the pRB/plO7-binding region and the amino-terminal region which is deleted in d11135 but lacks the p53-binding region. Another mutant protein analyzed contains a single amino acid change that simultaneously disrupts pRB, p107, and p53 binding and presumably leaves the amino-terminal activity intact. It too is defective in lymphoid tumorigenesis and is further impaired in the induction of choroid plexus tumors, although it measurably perturbs the growth of choroid plexus cells (4) . Mutant d11135, which binds pRB, p107, and p53 but is defective in the amino-terminal function, readily induces T-cell lymphoma. Together, these studies suggest that T-antigen-induced lymphoma (at least in T cells) correlates with its p53-binding property. The present study suggests that additional T-antigen activities may be required for B-cell lymphomagenesis.
The generation of mice which are homozygous for a null mutation in p53 (11) provides additional evidence suggesting that p53 may play a role in controlling lymphoid cell growth. While loss of p53 still supports normal development to early adulthood, these mice develop tumors of certain cell types with increased frequency (11, 25) . The tumors that arise with greatest frequency (approximately two-thirds) are of lymphoid cell origin (11) . Interestingly, thymoma is the predominant lymphoma type (25) . This observation supports the notion that T antigen interferes with the function of p53. Of interest, choroid plexus tumors have not been observed in the p53 null mice, consistent with our observation that the p53-binding property of T antigen is not required for the production of these tumors (4) .
Further studies using T antigen in transgenic mice, together with gene disruption experiments, should help elucidate the mechanisms that different cell types utilize to maintain the growth control characteristic of their unique differentiated states. Ultimately a more direct approach would involve interfering with putative negative growth regulators in specific cell types without using transforming proteins such as T antigen. Until whole animal approaches utilizing antisense nucleic acids or cell-specific targeted gene mutation are further developed, the tumor virus proteins used in studies such as those described here provide a useful alternative.
